FOLFIRI regimen | 1000669-05-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: FOLFIRI regimen
• 英文别名: (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;5-fluoro-1H-pyrimidine-2,4-dione
• CAS: 1000669-05-5
• 化学式: C57H64FN13O15
• 分子量: 1190.2
• InChiKey: JYEFSHLLTQIXIO-SMNQTINBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  86
• 可旋转键数：
  14
• 环数：
  11.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  386
• 氢给体数：
  10
• 氢受体数：
  20

文献信息

• TREATMENT WITH ANTI-VEGF ANTIBODIES
  申请人：GENENTECH, INC.

  公开号：EP1629010A1

  公开（公告）日：2006-03-01
• METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER
  申请人：Deciphera Pharmaceuticals, LLC

  公开号：US20150246033A1

  公开（公告）日：2015-09-03

  The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.
• ANTIBODY AND CHECKPOINT INHIBITOR COMBINATION THERAPY
  申请人：Bionomics Limited

  公开号：US20190263925A1

  公开（公告）日：2019-08-29

  The present invention provides a combination therapy for treatment of a tumour in a subject. The combination therapy comprises administration of (i) an antibody directed against cancer stem cells and (ii) a checkpoint inhibitor.
• US9457019B2
  申请人：——

  公开号：US9457019B2

  公开（公告）日：2016-10-04
• [EN] TREATMENT WITH ANTI-VEGF ANTIBODIES<br/>[FR] TRAITEMENT AU MOYEN D'ANTICORPS ANTI-VEGF
  申请人：GENENTECH INC

  公开号：WO2005000900A1

  公开（公告）日：2005-01-06

  This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.